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ETS transcription factors ETV2, FLI1, and ERG1
specify pluripotent stem cells into induced vascular
endothelial cells (iVECs). However, iVECs are un-
stable and drift toward nonvascular cells. We show
that human midgestation c-Kit lineage-committed
amniotic cells (ACs) can be reprogrammed into
vascular endothelial cells (rAC-VECs) without transi-
tioning through a pluripotent state. Transient ETV2
expression in ACs generates immature rAC-VECs,
whereas coexpression with FLI1/ERG1 endows
rAC-VECswith a vascular repertoire andmorphology
matching mature endothelial cells (ECs). Brief
TGFb-inhibition functionalizes VEGFR2 signaling,
augmenting specification of ACs into rAC-VECs.
Genome-wide transcriptional analyses showed that
rAC-VECs are similar to adult ECs in which vas-
cular-specific genes are expressed and nonvascular
genes are silenced. Functionally, rAC-VECs form
stable vasculature in Matrigel plugs and regenerat-
ing livers. Therefore, short-term ETV2 expression
and TGFb inhibition with constitutive ERG1/FLI1
coexpression reprogram mature ACs into durable
rAC-VECs with clinical-scale expansion potential.
Banking of HLA-typed rAC-VECs establishes a vas-
cular inventory for treatment of diverse disorders.INTRODUCTION
The generation of human endothelial cells (ECs) from nonvas-
cular cell sources has great therapeutic potential for treatment
of injured organs. Furthermore, this approach would help toidentify developmental pathways that modulate the hierarchical
specification of organotypic adult ECs. However, the cultivation
of stable ECs to clinical scale has not been achieved. Adult-
derived ECs have limited expansion potential. Likewise, differen-
tiation of pluripotent stem cells, including induced pluripotent
stem cells (iPSC) and human embryonic stem cells (hESCs),
into induced vascular endothelial cells (iVECs) results in the
generation of ECs that often proliferate poorly and drift into
nonvascular lineages (James et al., 2010). Endothelial progenitor
cells (EPCs) (Lyden et al., 2001; Rafii et al., 2002; Rafii and Lyden,
2003; Jin et al., 2006) and endothelial colony-forming cells
(ECFCs) (Yoder et al., 2007) show significant expansion potential
when grown in plasma (Reinisch et al., 2009). However, whether
EPCs and ECFCs maintain their vascular identity after serial
passaging is unknown. The shortcomings of existing strategies
to generate mature and stable ECs are likely attributable to an
insufficient appreciation of the transcription factors (TFs) and
microenvironmental cues that establish durable tissue-specific
vascular cells.
Members of the E-twenty six (ETS) family of TFs, including
ETV2 (Lee et al., 2008), FLI1 (Liu et al., 2008), and ERG
(McLaughlin et al., 2001), regulate vascular development and
angiogenesis (De Val and Black, 2009). These TFs drive the
expression of genes associated with EC development and func-
tion. Adult ECs constitutively express several ETS factors, such
as FLI1 and ERG (isoforms 1 and 2), whereas ETV2 is transiently
expressed during embryonic development and is absent in adult
ECs (Hollenhorst et al., 2007). Although many of these TFs play
key roles in vascular specification (Liu and Patient, 2008; Pham
et al., 2007), it is not knownwhether they can switch on EC genes
in nonvascular cells. Here, we show that differentiation of hESCs
into iVECs (hESC/EC) is driven by the expression of ETV2,
ERG1, and FLI1. However, iVECs generated by this approach
are unstable and often lose their vascular identity.
In search of readily accessible and proliferative human cells
for generation of authentic ECs, we identified human amnioticCell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc. 559
Figure 1. ACs Transduced with ETS-TFs and TGFb Inhibition Display a Proliferative and Stable Vascular Phenotype
(A) Schematic of time course of rAC-VEC reprogramming platform. ETV2, FLI1, and ERG1 (ETS-TFs) transduced ACs were cultured in the presence of TGFb
inhibitor (SB431542, 5 mM) and assayed for expression of EC markers.
(B) EC marker expression of ACs transduced with lentiviruses for ETS-TFs (+) or equivalent doses of empty-vector lentivirus () plus TGFb inhibition. All
subsequent control (ctrl) samples were transduced with empty-vector virus unless otherwise noted. (Triplicate samples: *p < 0.01 compared to control ACs for
days 7–28. Error bars represent standard error).
(C) Cellular expansion of ACs transduced with ETV2, FLI1, and/or ERG1 plus TGFb inhibition for 3 weeks (n = 3, p < 0.05 for all conditions).
(D) Cellular expansion of ACs transduced with ETS-TFs plus TGFb inhibition for 7 weeks (n = 4 independent experiments). Fluorescence-activated cell sorting
(FACS) performed at week 7 reveals that nearly 100% of these cells express VE-cadherin (VE-cad).
(E) Cellular expansion of rAC-VECs and hESC-derived iVECs (hESC/ECs) transduced with ETS-TFs plus TGFb inhibition for 3 weeks (n = 3, p < 0.05).
(F) FACS reveals percentage of VE-cadherin+ cells following transduction by ETS-TFs.
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fluid-derived cells (ACs) as an ideal source of genetically diverse,
nonvascular cells that are amenable to transcriptional reprog-
ramming into vascular ECs (rAC-VECs). Freshly isolated ACs
are obtained from individuals with broad genetic and ethnic
backgrounds and are routinely cultured from the amniotic fluid
of midgestation human fetuses for diagnostic purposes. They
display high proliferative potential and can be HLA typed, cryo-
preserved, and stored for clinical use.
Three subclasses of lineage-committed ACs have been iden-
tified: epithelioid (E type), amniotic fluid (AF type) and fibroblastic
(F type) (Bossolasco et al., 2006). E-type ACs presumably origi-
nate from fetal skin and mucosa, whereas F-type cells are
derived from connective tissue. A rare subset of ACs is c-Kit+
(CD117+) multipotent amniotic fluid stem cells (AFS) (De Coppi
et al., 2007). Incubation of naive ACs or preselected c-Kit+ AFS
in angiogenic culture conditions has led to the outgrowth of
EC-like cells (Benavides et al., 2012; De Coppi et al., 2007; Ko¨nig
et al., 2012; Zhang et al., 2009). However, it is unknown whether
these EC-like cells express a complete repertoire of EC genes,
nor has it been verified that their original AC signature is erased.
Here, we report that, within 4 days of enforced expression of
ETV2, FLI1, and ERG1 with TGFb inhibition in mature lineage-
committed c-Kit ACs, EC-specific genes are switched on.
Modular 2 week ETV2 expression and 3 week TGFb suppres-
sion, along with constitutive FLI1/ERG1 coexpression, turned
on and locked in the expression of EC genes in ACs and, im-
portantly, suppressed expression of nonvascular genes. Attenu-
ation of TGFb signaling was necessary to functionalize the
VEGFR2 signaling pathway, supporting expansion of abundant
rAC-VECs without loss of EC identity. Genome-wide transcrip-
tome analyses showed that rAC-VECs express a complete
vascular signature that is similar to adult ECs, such as human
umbilical vein ECs (HUVECs) and adult liver sinusoidal ECs
(LSECs). rAC-VECs established functional, patent, and long-
lasting vessels in immunocompromised mice. These data set
forth two important findings: (1) midgestation lineage-committed
ACs may possess a unique chromatin plasticity profile that
enables reprogramming of these cells into a large number of
vascular cells without the need for passing through a pluripotent
state and (2) constitutive coexpression of FLI1/ERG1 in combi-
nation with transient expression of ETV2 and TGFb pathway inhi-
bition provide for an efficient means to reprogram nonvascular
cells into proliferative, stable, and long-lasting rAC-VECs that
maintain their vascular identity upon serial passaging.
RESULTS
ETV2, FLI1, and ERG1 Differentiate hESCs into iVECs
that Are Unstable and Have Limited Proliferative
Potential
Current protocols to derive vascular cells from pluripotent stem
cells (hESCs and iPSCs) generate iVECs that have often limited(G) Immunofluorescence micrographs stained with antibodies to VE-cadherin an
VECs) and ETS-TF-transduced hESC-derived VE-cadherin+CD31+VEGFR2+ iVEC
controls. VE-cadherin (green stain), SMA (red stain), DAPI (blue stain). White arr
represent standard error of triplicate samples.
See also Figures S1 and S2.expansion potential and are unstable (James et al., 2010). As
such, we sought to identify TFs that are essential for vasculo-
genic specification of ECs and maintenance of iVECs. To this
end, we used an established model of hESC differentiation into
iVECs (James et al., 2010) (Figure S1A available online). Using
microarray profiling, we found that ETV2, FLI1, and ERG are
key ETS family TFs that are expressed during iVEC generation
(Figure S1B). Of note, ETV2 was expressed transiently, whereas
FLI1 and ERG were constitutively expressed as hESCs transi-
tioned to iVECs. Because, as compared to ERG2, ERG1 isoform
was more abundant and functionally active in ECs (i.e., HUVECs
and LSECs), we used ERG1 in protocols for the derivation of ECs
from hESCs and ACs.
To determine whether enforced overexpression of ETV2, FLI1,
and ERG1 (ETS-TFs) would augment the specification and
stability of iVECs, hESCs were incubated with BMP2 and
VEGF-A for 10 days to generate VEGFR2+CD31 VE-cadherin
cells, which are vascular precursors of iVECs. Subsequently,
these cells were transduced with lentiviral vectors expressing
cDNA for ETV2, FLI1, and ERG1 or control virus (Figure S1A).
After culturing cells with VEGF-A, FGF-2, and TGFb inhibitor,
we observed amodest increase in VEGFR2+CD31+VE-cadherin+
iVECs (hESCs/ECs) among ETS-TF transduced cells com-
pared to controls (Figure S1C). However, VEGFR2+CD31+VE-
cadherin+ iVECs generated from both ETS-TF transduced and
untransduced cells failed to proliferate beyond 3 weeks and
often drifted into non-EC cell types. Therefore, despite enforced
expression of ETS-TFs, hESC-derived iVECs are unable to
sustain their proliferative potential and EC identity.
ETS-TFs Reprogram ACs into Proliferative and Stable
rAC-VECs
We screened various adult and fetal nonvascular cells for their
ability to be reprogrammed into ECs and found that EC-specific
genes in adult fibroblasts and mesenchymal cells were only
minimally induced by ETS-TFs (data not shown). However, midg-
estation mature lineage-committed ACs proved to be highly re-
programmable. Cultured ACs were transduced singularly and
in combination with lentiviral ETS-TFs (ETV2, FLI1, and ERG1)
(Figure 1A). As TGFb inhibition is essential in the derivation of
iVECs from hESCs (James et al., 2010), ACs were also cultured
in the presence of TGFb receptor inhibitor or neutralizing mAbs
to TGFb ligands. Transduction of ACs with lentiviruses encoding
ETV2, FLI1, or ERG1 led to adequate levels of corresponding
mRNAs and protein for several months (Figures S2A and S2B).
Whereas individual ETS-TFs turned on distinct EC genes (data
not shown), ACs transduced with all three ETS-TFs displayed
robust induction of multiple EC markers within 7 days, which
lasted for 1 month and beyond (Figure 1B), suggesting that a
combination of these factors was necessary to activate the full
complement of genes associated with EC identity and maturity.
Transduction of ACs with ETS-TFs, especially ETV2, led to ad smooth muscle a-Actin (SMA) are shown for ETS-TF-transduced ACs (rAC-
s plus TGFb inhibition for 3 weeks. HUVECs and smooth muscle cells serve as
ows indicate junctional staining of VE-cadherin. Scale bar, 25 mm. Error bars
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rapid increase in cell numbers compared to untransduced cells
(Figure 1C). Starting with 105 ACs transduced with ETV2, FLI1,
and ERG1, nearly 30 million VE-cadherin+ rAC-VECs grew out
by week 3 and increased to more than 6 billion cells by week 7
(Figure 1D).
Following transduction with ETS-TFs and TGFb inhibition,
rAC-VECs generated from ACs expanded to numbers nearly
30-fold higher than ETS-TF transduced or untransduced iVECs
derived from hESCs (hESCs/ECs) (Figure 1E). Furthermore,
a noticeable decrease in VE-cadherin+ cells was seen over
successive passages of ETS-TF transduced or untransduced
hESC-derived iVECs compared to AC-derived rAC-VECs trans-
duced with ETS-TFs (Figure 1F). This ‘‘drift’’ away from an EC
phenotypewithin the hESC-derived iVEC populationwas verified
by staining with smooth muscle a-actin (SMA) antibody (Fig-
ure 1G, boxes iii, iv, and vi). ACs transduced with ETS factors
were negative for this non-EC marker (Figure 1g, box ii); rather,
they exhibited the typical junctional VE-cadherin expression
pattern found on other adult EC types, such as human umbilical
vein ECs (HUVECs: Figure 1g, box v) and human adult liver sinu-
soidal ECs (LSECs; Figure S2C, box iii). Thus, ACs are more
amenable to transcriptional reprogramming into stable ECs
than are hESCs or adult fibroblasts.
ACs Are Devoid of EC Precursor Cells
Subsets of c-Kit+ multipotent ACs, which compose% 1% of the
AC population (De Coppi et al., 2007), could potentially differen-
tiate into ECs. Thus, to exclude the possibility that ECs are exclu-
sively borne out from a multipotent or pluripotent subpopulation
of ACs, we assessed the presence of pluripotency markers. The
overwhelming majority of ACs was negative for OCT4 protein
(Figure 2A), confirming results from other groups (Jezierski
et al., 2010). Near undetectable mRNA expression levels for
OCT4 (Figure 2B, top), SOX2 (Figure 2B, bottom), and NANOG
(data not shown) further suggested that only a very small subset
of ACs cells could be pluripotent or multipotent.
Notwithstanding, to determine whether ECs could grow
out from a pluripotent or pre-existing EC precursor cell, we
cultured ACs without transduction of ETS-TFs in optimal EC
growth media (EM) and TGFb inhibitor in normoxic conditions.
We did not detect growth of any stable and fully committed
ECs, verifying that cultured ACs are devoid of pre-existing vas-
cular precursor cells that would generate authentic ECs (Fig-
ures S3A–S3B).
c-Kit Lineage-Committed Mature ACs Are
Reprogrammed into rAC-VECs
ACs are composed of undifferentiated cells expressing c-Kit,
Tra1-60, Tra1-81, and SSEA-3, SSEA-4, as well as lineage-
committed cells, phenotypically marked as E-cadherin+ (E-
Cad, CD324), EpCAM+ (CD326), and CD24+ cells (Figure 2C).
To determine whether ETS-TFs could directly reprogram the
proliferative and well-defined populations of lineage-committed
ACs into rAC-VECs, we depleted c-Kit+ cells from the AC pool.
Next, mature epithelioid cells (EpCAM+Tra1-81c-Kit) and
mesenchymal/fibroblastic cells (EpCAMTra1-81c-Kit) were
purified separately, transduced with ETS-TFs, and propagated
in the presence of TGFb inhibition. We observed a significant562 Cell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc.increase in VE-cadherin+ cells among the ETS-TF-transduced
EpCAM+Tra1-81c-Kit and EpCAMTra1-81c-Kit subpopu-
lations (Figure 2D). Immunostaining for EpCAM and VE-cadherin
confirmed the transition from an epithelioid-type AC to a rAC-
VEC (Figure 2E). Therefore, lineage-committed ACs are ame-
nable to TF-mediated reprogramming into rAC-VECs.
ETS-TFs Induce Expression of a Vascular Signature in
ACs
To assess the extent to which rAC-VECs acquire a vascular
signature, we temporally measured VE-cadherin and VEGFR2
surface expression on emerging nascent rAC-VECs (Figure 3A).
Four days after transducing TGF-b inhibited ACs with ETS-TFs,
VE-cadherin+ cells and, to a lesser extent, VEGFR2+ cells were
generated (Figure 3A, box ii). The percentage of cells expressing
these markers increased significantly over several weeks (Fig-
ure 3A, boxes iv and vi) such that, after 4 weeks of reprogram-
ming, the entire population (99%) of transduced ACs was
VE-cadherin+ (Figure 3B, box ii), of which nearly two-thirds
also showed VEGFR2 expression. In addition, the size and shape
of reprogrammed cells were similar to HUVECs (Figure 3B,
boxes iv–ix). We performed comparative genomic hybridiza-
tion (CGH) analysis to assess the genomic integrity of day 28
rAC-VECs. This analysis revealed no genomic abnormalities,
demonstrating that proliferating rAC-VECs are genetically stable
(Figure S4A).
Optimal Stoichiometry of ETS-TF Expression
Establishes Mature and Stable rAC-VECs
To create a homogenous population of mature rAC-VECs, we
performed clonal analyses. rAC-VECs generated from ACs by
transduction with ETS-TFs and TGFb inhibition were cultured
for 21 days. We then isolated single cells expressing VE-cad-
herin, VEGFR2, and CD31 (VE-cad+VEGFR2+CD31+ cells) and
plated them at a density of one cell per well in 96-well plates
for clonal expansion (Figure 3C). Within 21 days, 20% of
single-cell clones showed expansion potential (Figure 3D), with
individual clones yielding progeny with distinct phenotypes (Fig-
ure 3E, boxes i–iv). Whereas cells from clones 1–3 were all VE-
cadherin+, CD31 expression varied greatly among these clones.
Of note, nearly all clone 3 cells expressedCD31, whereas clone 1
yielded no CD31+ cells and clone 2 produced both CD31+ (18%)
and CD31 cells. Regardless of CD31 expression, all three
clones expanded beyond 4 weeks (Figure 3E, box v).
These differences in EC marker induction could be due to
differential levels of ETS-TF expression (Figure 3E, boxes vi–
viii). Both ERG1 and FLI1 were expressed in clone 3, suggesting
that these factors turn on CD31 expression (Figure 3E). By
contrast, ETV2 correlated negatively with CD31 expression.
Thus, clone 3 had the appropriate combination of ETS-TF
expression to induce VE-cadherin, VEGFR2, and CD31. Immu-
nostaining of this clone confirmed the presence of VE-cadherin,
CD31, ESAM, and JAM-A at cell junctions (Figures 3F and S5A).
The disappearance of EpCAM in rAC-VECs (Figure 3F) indicates
that the original nonvascular signature of these cells is being
stripped away. Thus, expression of the proper stoichiometry of
ETS-TFs is critical for generating rAC-VECs that are capable of
achieving and maintaining optimal mature EC identity.
Figure 2. Tra1-81c-Kit Lineage-Committed Mature Mesenchymal/Fibroblastic and Epithelioid ACs Are Reprogrammable into rAC-VECs
(A) hESCs (i), HUVECs (ii), and ACs (AC1 to AC4: iii–vi) were stained for OCT4 protein (pink). DAPI (blue). Scale bar, 100 mm.
(B) OCT4 (upper graph) and SOX2 (lower graph) mRNA expression were measured in hESCs, HUVECs, and ACs (AC1, AC5, AC6). Red bars: hESC data (y axis
scale, left side of graph). Blue bars: AC and HUVEC data (y axis scale, right side of graph). (OCT4 and SOX2: *p < 0.002 compared to ACs and to HUVECs).
(C) FACS of ACs indicate the presence of lineage-committed and -uncommitted cells. One representative cell line is depicted (i–iv). Specific markers tested are
indicated on x and y axes as Log fluorescent intensity (Log. Fl. Int.), showing the percentage of cells positive for that marker. Chart (right) displays mean values for
percentage of cells expressing designated markers across 15 independent cultured AC samples (SE: standard error).
(D) (Left graph) Cellular expansion of ETS-TF-transduced EpCAM+Tra1-81c-Kit and EpCAMTra1-81c-Kit ACs plus TGFb inhibition for 4 weeks. (Right
graph) FACS reveals percentage of VE-cadherin+ cells following transduction with ETS-TFs (n = 3, p < 0.05).
(E) Immunofluorescencemicrographs are shown for ETS-TF-transduced EpCAM+Tra1-81c-KitACs in the presence of TGFb inhibition for 4weeks. EpCAM (red
stain), VE-cad (green stain), DAPI (blue stain). Scale bar, 25 mm. Error bars represent standard error of triplicate samples.
See also Figure S3.
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Figure 3. Optimal Stoichiometric Ratios of ETV2, ERG1, and FLI1 Are Essential for Generation of Clonal Mature rAC-VECs
(A and B) FACS reveals VE-cad and VEGFR2 expression on emerging rAC-VECs at 4 days (A, i and ii.), 12 days (A, iii and iv), 21 days (A, v and vi), and 28 days (B, I
and ii) following transduction with ETS-TFs plus TGFb inhibition (control ECs: HUVECs; b, iii.). The morphology (b, iv– vi) and size (b, vii–ix) of emerging rAC-VECs
approximated those of control ECs. Scale bar, 50 mm.
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Clonally Derived rAC-VECs Display a Transcriptome
Profile that Is Similar to Mature ECs
Transcriptome sequencing (RNA-seq) was performed on rAC-
VECs derived from ACs. These genome-wide analyses of rAC-
VECs were then compared to the transcriptomes of HUVECs,
LSECs, and non-EC types, including CD34+ hematopoietic cells
(CD34+), bone marrow stromal cells (BMS), and naive control
ACs (Amni ctrl). A significant number of vascular genes were up-
regulated in nonclonal (rAC-VEC) and clonal (rAC-VEC clone 3
and rAC-VEC clone 4) derived rAC-VECs compared to naive
ACs (Figure 4A). Furthermore, the expression levels of these
induced EC genes approached those seen in in-vitro-cultured
HUVECs and LSECs, supporting the notion that rAC-VECs
have attained a complete EC identity. Angiocrine factors that
regulate EC-driven organ regeneration (Butler et al., 2010b;
Ding et al., 2010, 2011; Kobayashi et al., 2010) and tumor growth
(Butler et al., 2010a), including BMPs, Notch-ligands, IGFs,
CSFs, Kit-ligand, and semaphorins, were all switched on in the
rAC-VECs as well. Importantly, non-EC genes normally ex-
pressed in ACs, such as smooth muscle actin, musclin, and cal-
ponin-1, were silenced in rAC-VECs.
We then compared rAC-VEC and adult EC transcriptomes
obtained from RNA-seq by performing three-dimensional multi-
dimensional scaling (3D-MDS) (Figure 4B and Movie S1) and
hierarchical clustering analyses (Figure 4C). A tight association
of clonal and nonclonal derived rAC-VECs was seen with
HUVECs and LSECs, whereas BMS, lung-derived epithelial cells
(Hackett et al., 2012), and CD34+ hematopoietic cells showed no
similarities to rAC-VECs. Of note, rAC-VECs did not express
hematopoietic markers, ruling out the possibility that FLI1 and
ERG1 induced hematopoietic identity. Therefore, genome-wide
analyses demonstrate that enforced expression of ETV2, FLI1,
and ERG1 with TGFb inhibition reprogram ACs into mature
rAC-VECs (while silencing non-vascular genes) that resemble
authentic mature ECs in global gene expression.
Short-Term TGFb Inhibition Permanently Functionalizes
VEGFR2 Signaling in rAC-VECs
ETS-TF-transduced ACs produced both TGFb and its receptors
(Figure 4A), raising the possibility that an autocrine/juxtacrine
loop might favor endothelial-mesenchymal transition (Endo-
MT) and prevent rAC-VEC generation (Zeisberg et al., 2007).
Thus, ETS-TF-transduced ACs were cultured with and without
neutralizing mAb to TGFb ligands or a TGFb inhibitor for 21
days. Even in the absence of exogenous TGFb ligand, basal
levels of phosphorylated SMAD2 (P-SMAD2) were active in
both control and ETS-TF-transduced ACs (Figure 5A, lanes 1(C) Schematic of single-cell clonal expansion protocol. ACs were transduced wit
used to isolate VE-cad+VEGFR2+CD31+ cells. These rAC-VECs then underwen
several weeks. On average, 20% of individual plated cells formed colonies.
(D) Single-cell clonal expansion over 3 weeks following VE-cad+VEGFR2+CD31+
(E) FACS of specific rAC-VEC clone 1, clone 2, and clone 3 (boxes ii–iv) reveals V
protocol (i.e., 3 weeks post VE-cad+VEGFR2+CD31+ isolation). Cellular expansion
protocol) over subsequent 5 weeks (box v). Expression levels for ETV2, FLI1, and
(F) Immunofluorescence micrographs are shown for control (ctrl) ACs, clonal rAC
(red stain: ii, vii, and xii), ESAM (red stain: iii, viii, xiii), JAM-A (red stain: iv, ix, xiv
represent standard error of triplicate samples.
See also Figures S4 and S5.and 2). This correlated with an absence of total and phosphory-
lated VEGFR2 protein in these TGFb-activated control and
ETS-TF-transduced ACs (Figure 5B, lanes 1–4). However, addi-
tion of mAb to TGFb ligands abrogated P-SMAD2 expression in
rAC-VECs (Figure 5A, lanes 7 and 8) upregulating VEGFR2
protein (Figure 5B, lanes 11 and 12). Importantly, rAC-VECs
treated with mAb to TGFb ligands were responsive to VEGF-A
stimulation, as shown by the phosphorylation of VEGFR2 (Fig-
ure 5B, lane 12). Despite supplementation with TGFb ligand
(Figure 5A, lanes 3–6) or pulsed with TGFb ligand stimulation
(Figure 5A, lanes 11–16), the presence of TGFb inhibitors pre-
vented SMAD-2 phosphorylation, allowing for upregulation of
VEGFR2 protein (Figure 5B, lanes 7–10) and VEGF-A dependent
phosphorylation (Figure 5B, lanes 8 and 10). Of note, TGFb-acti-
vated rAC-VECs failed to attain ECmorphology (Figure 5C, box ii
versus vi), whereas inhibition of TGFb signaling (Figure 5C, boxes
iii, iv, and v) endowed rAC-VECs with typical cobblestone mor-
phology of ECmonolayers (Figure 5C, box vi). Thus, suppression
of TGFb signaling functionalizes VEGFR2, preserving the vas-
cular identity of rAC-VECs (Figure 5D).
To determine whether continuous suppression of TGFb sig-
naling was necessary to sustain rAC-VEC stability, we sequen-
tially removed TGFb inhibition following ETS-TF transduction
(Figure 5E, left). Upon removal of TGFb inhibition at day 14 after
transduction with ETS-TFs, we noticed a drop in VEGFR2+ cells
during the ensuing 7 days of cell growth (Figure 5E, left, white
bar). However, when TGFb inhibition was removed at day 21
after transduction with ETS-TFs, the percentage of VEGFR2+
cells was retained (Figure 5E, left, gray bar). Of note, manipula-
tion of the TGFb pathway had no effect on VE-cadherin expres-
sion in rAC-VECs (Figure 5E, right graph). Thus, abrogation of
TGFb signaling for only 3 weeks is sufficient to permanently
functionalize VEGFR2 signaling, maintaining long-term vascular
identity and stability of rAC-VECs.
AC-Derived rAC-VECs Are Engraftable and Form
Functional Perfused Vessels
We employed in vitro and in vivo models to assess whether rAC-
VECs acquired full angiogenic potential. A tube formation assay
using Matrigel as a substrate showed that day 21 rAC-VECs, but
not naive ACs, were capable of forming tubes in vitro (Figure 6A).
In addition, uptake of acetylated LDL (Ac-LDL) in rAC-VECs was
similar to HUVECs (Figure 6B).
We then tested for the ability of rAC-VECs to establish
functional vasculature in two in vivo models. In one model,
GFP-labeled day 42 rAC-VECs treated with either constant or
short-term (21 days) TGFb inhibition in culture were loaded intoh ETS-TFs plus TGFb inhibition. At day 21, monoclonal antibodies (mAb) were
t automated single-cell plating into a 96-well format for clonal expansion for
isolation. Scale bar, 100 mm.
E-cad, VEGFR2, and CD31 surface expression at day 42 of clonal expansion
of rAC-VEC clones from time of single-cell plating (day 21 of clonal expansion
ERG1 of rAC-VEC clones at day 42 of clonal expansion protocol (boxes vi–viii).
-VECs (clone 3, day 42), and HUVECs. VE-cad (green stain: i, vi, and xi), CD31
), EpCAM (red stain: v, x, xv), DAPI (blue stain). Scale bar, 50 mm. Error bars
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Figure 4. rAC-VECGlobal Gene TranscriptomeReveals that Vascular Genes Are TurnedOnwhile Nonvascular Genes Are Silenced,Matching
Expression Profile of Mature ECs
(A) ETS-TF-transduced ACs (rAC-VEC) as well as two rAC-VEC clones (rAC-VEC clone 3 and rAC-VEC clone 4) cultured for 2 months with TGFb inhibition
underwent RNA-seq analysis. (rAC-VEC clone 4 has a similar ETS-TF expression profile to that of rAC-VEC clone 3; data not shown). The expression profiles of
these rAC-VEC samples were compared to human umbilical cord blood-derivedCD34+ cells (CD34+), human bonemarrow stromal cells (BMS), naive human ACs
(Amni ctrl), HUVEC, and LSEC. Heatmaps of relative transcription levels are shown.
(B) Three-dimensional MDS plots (3D MDS) were generated based on all pairwise distances between the global transcriptome-wide RNA-seq profiles of the
samples shown here, including adult lung airway epithelial cells (Hackett et al., 2012). This analysis shows a tight colocalization of clonal and nonclonal rAC-VECs
with HUVECs and LSECs, thus indicating that their genome-wide expression profiles are highly similar. Conversely, nonvascular cell types, such as BMS,
epithelial cells, and CD34+ hematopoietic cells, manifest no similarities to rAC-VECs. This analysis was not biased toward any gene set or processes: all > 30,000
RefSeq transcripts whose expression was quantified by RNA-seq were used to calculate distances between samples.
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Matrigel plugs supplemented with VEGF-A and FGF-2 and were
injected into immunocompromised NOD-SCID/IL2Rg/ (NSG)
mice (Figure 6C). Two weeks later, following intravital labeling
of the vasculature by perfusion with Alexa568-Isolectin-B4
(10 min prior to sacrificing the mice) to identify patent vessels,
Matrigel plugs were removed for analysis. Although naive ACs
failed to form any capillaries (Figure 6C, box ix), rAC-VECs
treated with constant TGFb inhibition formed numerous func-
tional vessels of varying caliber that anastomosed to the host
vasculature. This was corroborated by colocalization of GFP
signal with isolectin marker (Figure 6C, box x). Similarly, rAC-
VECs subjected to short-term TGFb inhibition showed an abun-
danceof perfused vessels, underscoring their functionality in vivo
(Figure 6C, boxes xi and xii).
Intrasplenic transplantation of ECs results in the engraftment
of these cells into the liver sinusoidal vessels of mice that
have undergone 70% partial hepatectomy (Ding et al., 2010).
We used this in vivo model to interrogate the potential of rAC-
VECs to incorporate long-term into the NSG mouse liver vascu-
lature. Threemonths following intrasplenic transplantation of 53
105 GFP-labeled day 21 rAC-VECs, the mice were perfused with
Alexa568-Isolectin-B4 to identify functional vessels. The number
of perfused vessels engrafted with human GFP+ rAC-VECs was
determined by staining with mAbs specific to human CD31
(hCD31). Of note, we detected the presence of human GFP+
Isolectin+hCD31+ rAC-VECs within 5%–10% of the regenerated
liver sinusoidal vessels (Figures 6D and 6E). Thus, rAC-VECs can
engraft and form durable patent vasculature in regenerating liver
and establish functional perfused vessels in Matrigel plugs.
Function andVascular Identity of rAC-VECs Is Preserved
following Suppression of ETV2
ETV2 is transiently expressed during vascular development but
is absent from mature fetal and adult ECs (Kataoka et al.,
2011). This is similar to our observation that rAC-VEC clones
with low ETV2 levels and appropriate ERG1 and FLI1 levels
represent populations of rAC-VECs that have achieved a mature
vascular fate. Therefore, we examined whether short-term ex-
pression of ETV2, in conjunction with sustained expression of
FLI1 and Erg1, might initiate reprogramming and then lock in
permanent rAC-VEC identity. Using a doxycycline-dependent
inducible (Tet-off) expression system to control ETV2 production
(inducible ETV2: iETV2), iETV2/FLI1/ERG1 were transduced in
ACs and cultured with TGFb inhibition for 14 days (Figure 7A).
Next, cells were treated with doxycycline to suppress iETV2
expression without interfering with the expression of FLI1 and
ERG1. ACs transduced with iETV2/FLI1/ERG1 expressed VE-
cadherin and CD31 in both dox-treated (iETV2-suppressed)
and untreated cells beyond 4weeks. Of note, 7 and 14 days after
iETV2 was silenced, there was a higher percentage of VE-cad-
herin+CD31+ rAC-VECs compared to untreated rAC-VECs (Fig-
ure 7B). Western blot analysis confirmed that ETV2 protein
expression had indeed been silenced (Figure 7C) in dox-treated(C) Hierarchical clustering of rAC-VEC and non-rAC-VEC samples. The same s
profiles were used as those used for 3D-MDS by performing average linkage clus
nonclonal rAC-VECs, but not nonvascular cells cluster closely with HUVECs and
See also Movie S1.cells, indicating that ETV2was no longer required for maintaining
VE-cadherin expression in rAC-VECs.
ERG1 synergizes with FLI1 to enhance and sustain CD31
expression in maturing rAC-VECs (Figures 3E and 7B). Thus,
its importance in reprogramming was assayed by transducing
TGFb inhibited ACs with iETV2/FLI1 in the absence of ERG1
(Figure S6A). These cells were then split into two fractions at
day 14, one of which was treated with doxycycline to suppress
iETV2 expression without perturbing FLI1 expression. The emer-
gence of VE-cadherin+CD31+ rAC-VECs generated from ACs
transduced with iETV2/FLI1/ERG1 was accelerated compared
to ACs lacking ERG1 transduction (Figure 7B versus Figure S6B).
In day 28 iETV2/FLI1/ERG1 transduced ACs, in which iETV2
expression has been suppressed for 2 weeks, there was coloc-
alization of VE-cadherin andCD31 (Figure S6C), aswell as induc-
tion of numerous EC markers (Figure S7A).
To assess the functionality of rAC-VECs generated via tran-
sient iETV2 expression in vivo, GFP-labeled iETV2/FLI1/ERG1
transduced ACs were cultured for 14 days, at which time
iETV2 expression was suppressed. Subsequently, these cells
were grown for another 28 days (d42 rAC-VECs), loaded into
Matrigel plugs, and injected into NSG mice. Two weeks later,
following intravital labeling of the vasculature by perfusion with
Alexa568-Isolectin-B4, Matrigel plugs were removed for analysis
(Figures 7D and S7B). There was colocalization of GFP, human
CD31 (hCD31), and isolectin-marked cells, verifying that rAC-
VECs no longer expressing iETV2 were still functional and
capable of anastomosing to the host vasculature. Therefore, ex-
pression of ETV2 for only 2 weeks, along with constitutive coex-
pression of FLI1 and ERG1, confers rAC-VECs with permanent
mature EC identity.
DISCUSSION
ETS-TFs Reprogram ACs into Durable and Expandable
Mature rAC-VECs
Derivation of abundant, engraftable human ECs could benefit
patients with vascular disorders and uncover the identity of
TFs and microenvironmental cues that drive organotypic EC
specification. However, the purification and expansion of adult
ECs is technically cumbersome. Current strategies to derive
ECs from pluripotent stem cells even after transduction with
ETS-TFs also generate unstable iVECs that have limited expan-
sion potential (Figures 1E–1G). Moreover, recent reports of
directly reprogramming fibroblasts into EC-like cells (Margariti
et al., 2012) still required the introduction of pluripotency factors.
In the absence of these factors, fibroblasts failed to repro-
gram. Here, we have identified an alternative source of human
lineage-committed ACs that can be reprogrammed into prolifer-
ative functional ECs without utilizing pluripotency factors, which
we refer to as rAC-VECs. We show that enforced expression
of FLI1/ERG1 with transient expression of ETV2 and TGFb in-
hibition reprograms ACs into rAC-VECs, which possess theamples and pairwise distances between global transcriptome-wide RNA-seq
tering. Like the 3D-MDS analysis, hierarchical clustering shows that clonal and
LSECs.
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Figure 5. Short-Term TGFb Inhibition for 3 Weeks Upregulates and Permanently Functionalizes VEGFR2 in rAC-VECs
(A) Western blot analysis of day 21 rAC-VECs that were treated ± TGFb ligand neutralizing mAB (TGFb ligand mAb, directed against b1, b2, and b3) or TGFb
inhibition. This experiment was performed ± TGFb ligands (TGFb1 and TGFb3) to delineate the extent of TGFb receptor activity. ETS-TF-transduced ACs were
incubated ± TGFb ligands (10 ng/ml) every 2 days (constant) with or without TGFb ligand mAb (10 mg/ml) or TGFb inhibitor. On day 21, ETS-TF-transduced ACs
were serum starved for 4 hr and then treated ± one dose of TGFb ligands (10 ng/ml) for 45 min (pulse) ± TGFb ligand mAb or TGFb inhibitor. Following day 21
treatment, all cells were assayed for phosphorylated SMAD2 (P-SMAD2), total SMAD2, and GAPDH.
(B) Western blot analysis of day 21 rAC-VECs that were treated ± constant TGFb ligands, with or without TGFb ligand mAb or TGFb inhibitor. On day 21, ETS-TF-
transduced ACs were serum starved for 4 hr and then treated ± VEGF-A (50 ng/ml) for 5 min. Following day 21 treatment, cells were assayed for phosphorylated
VEGFR2 (P-VEGFR2), total VEGFR2, and GAPDH.
(C) Cell morphology of control ACs (i), ETS-TF transduced ACs (ii–v), and HUVECs (vi) was noted for indicated treatments with TGFb ligands, TGFb ligand mAb,
and/or TGFb small molecule inhibitor. Scale bar, 100 mm.
(D) FACS reveals expression of VEGFR2 in day 21 ETS-TF-transduced ACs in the presence (black bars) or absence (white bars) of persistent TGFb inhibition.
(E) FACS reveals surface expression of VEGFR2 (left graph) and VE-cad (right graph) in day 28 ETS-TF-transduced ACs. Black bars: cells subjected to persistent
TGFb inhibition; EC marker expression was assessed on days 14, 21, and 28. White bars: cells subjected to TGFb inhibition for 14 days; EC marker expression
was assessed on day 21. Gray bars: cells subjected to TGFb inhibition for 21 days; ECmarker expression was assessed on day 28. Error bars represent standard
error of triplicate samples.
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morphology and long-lasting angiogenic repertoire of generic
and naive ECs (Figure 7E).
Transduction of ACs with ETS-TFs not only resulted in
complete activation of a vascular signature, but also turned off
nonvascular programs in ACs. rAC-VECs are highly proliferative
and stable, capable of undergoing 6 3 104-fold expansion in
50 days while maintaining expression of adhesion molecules,
ECM proteins, and angiocrine factors, all of which establish their
vascular function. With more amniocentesis being performed
world-wide, we expect that genetically matched ACs will be
available to generate sufficient numbers of durable and engraft-
able rAC-VECs for the treatment of vascular disorders and to
orchestrate organ regeneration.
Lineage-Committed ACs Are Amenable to
Reprogramming into rAC-VECs
c-Kit+ cells represent a rare AC subpopulation (%1%) that is
multipotent (De Coppi et al., 2007). However, the majority of
ACs are c-Kit, comprising lineage-committed cell types (Fig-
ure 2C). Furthermore, in the specimens tested here, we did not
detect any significant expression of pluripotency genes, such
as OCT4, NANOG, and SOX2. Thus, it is unlikely that rAC-
VECs arise from pluripotent or c-Kit+ multipotent cells because
of their scarcity and because our attempts to generate rAC-
VECs without ETS-TF transduction were unsuccessful. Regard-
less, our reprogramming strategy is effective in generating
rAC-VECs from mature c-Kit ACs. Within 4 days of ETS-TF
transduction, nearly 20% of transitioning c-Kit ACs expressed
VE-cadherin. Both lineage-committed EpCAM+Tra1-81c-Kit
epithelioid and EpCAMTra1-81c-Kit mesenchymal/fibro-
blastic ACs could be transcriptionally reprogrammed into rAC-
VECs, supporting the notion that rAC-VECs are primarily derived
from mature ACs.
How are such large numbers of mature ACs readily reprog-
rammed into rAC-VECs? ACs may be capable of generating
endothelium because they express essential ETS cofactors.
For example, ACs express FOXC2, which can partner with
ETV2 to bind vascular enhancers that possess FOX:ETS ele-
ments and drive expression of vascular genes (De Val et al.,
2008). It is also plausible that midgestation ACs possess a
uniquely plastic chromatin state, rendering them permissive
to transcriptional reprogramming. Therefore, ACs provide for a
universally reprogrammable and safe source of primary cells
for the generation of tissue-specific lineages and help identify
unrecognized chromatin states that are accessible to clusters
of organotypic TFs.
ETS-TFs Switch on Vascular-Specific Genes and Silence
the Expression of Nonvascular Genes in ACs
Hierarchical clustering and 3D-MDS analyses demonstrate that
the transcriptome of rAC-VECs is highly similar to prototypical
fetal (HUVEC) and adult (LSEC) mature ECs and differs drasti-
cally from nonvascular cells. Thus, rAC-VECs exclusively acquire
the global transcriptome of a generic vascular cell type while
simultaneously silencing their original nonvascular transcrip-
tional signature.
ETS-TF-mediated suppression of nonvascular transcription
programs in rAC-VECs is clinically relevant, as persistent expres-sion of nonvascular genes may result in malfunction of in-vivo-
engrafted rAC-VECs predisposing to vascular deformity and
thrombus formation. Indeed, engraftment of rAC-VECs into
Matrigel plugs or regenerating mouse liver led to the generation
of patent sinusoidal-like capillaries that manifested no evidence
of thrombosis for a duration of 3 months. Thus, rAC-VECs have
the capacity to adapt to the microenvironment within the liver
sinusoids establishing durable perfused vessels.
ETS-TF-Mediated Generation of Functional rAC-VECs
Requires Short-Term TGFb Inhibition for 3 Weeks
Transduction of ETS-TF into ACs without TGFb inhibition failed
to generate functional proliferative rAC-VECs. Of note, rAC-
VECs not only express TGFb1, -b2, -b3, and LTBPs, but also
TGFbRII and TGFbRI, resulting in constitutive SMAD2 phosphor-
ylation. Active TGFb signaling favors Endo-MT, hindering the
formation of rAC-VECs. TGFb also modulates stability of FLI1
protein and its capacity to bind DNA (Asano and Trojanowska,
2009). TGFb signaling abrogates VEGFR2 expression in ECs,
impairing proliferative and vasculogenic functions. Remarkably,
short-term inhibition of TGFb signaling for 3 weeks was suffi-
cient to permanently functionalize VEGFR2 and possibly other
unknown EC-specific signaling and transcriptional pathways.
Thus, reprogramming of ACs not only requires enforced expres-
sion of TFs, but also modulation of signaling pathways to estab-
lish stable rAC-VECs.
Transient ETV2 Expression with Sustained FLI1 and
ERG1 Maintains Vascular Maturity and Stability of
rAC-VECs
Adult ECs do not express ETV2 but do constitutively express
FLI1 and ERG1 (De Val and Black, 2009), suggesting that tran-
sient expression of ETV2 is sufficient to specify and lock in the
vascular fate. Similarly, ETV2 expression in ACs for 2 weeks
was sufficient to switch on multiple downstream EC-specific
ETS family TFs. The genes turned on by ETV2 were factors
that are essential for specification of ACs into functional ECs,
including VEGFR2, VE-cadherin, TIE1, TIE2, EDG-1, VEGFR1,
and Notch-signaling pathway genes.
Of note, ETV2 alone was insufficient to switch on all EC genes.
FLI1 and ERG1, meanwhile, turned on EC genes associated with
maturity, such as CD31, ECMs, and angiocrine factors. Hence,
ETV2 specifies ACs into immature endothelium, whereas FLI1
and ERG1 induce genes that render these progenitors into
mature functional ECs (Figure 7E).
It is unknown how genes targeted by ETV2 are sustained after
ETV2 expression is extinguished. One intriguing possibility is that
genes bound by ETV2 are epigenetically marked for sustained
activation. Alternatively, upon silencing of ETV2 expression,
FLI1, ERG1, and/or other unrecognized TFs arrive at formerly
ETV2-bound genomic targets to maintain long-term expression.
Indeed, deletion of FLI1 gene in adult ECs results in downregula-
tion of certain vascular-specific genes that modulate EC identity
(Asano et al., 2010). Thus, as we demonstrate here, constitutive
expression of FLI1 plays a seminal role in stabilizing rAC-VECs.
Similarly, ERG may also maintain the quiescence of ECs by
repressing the activity of NF-kB (Dryden et al., 2012; Yuan
et al., 2009) and safeguarding vascular permeability by enforcingCell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc. 569
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expression of Claudin-5 (Yuan et al., 2012) and VE-cadherin
(Birdsey et al., 2008). ERG is expressed in at least two isoforms
(ERG1 and ERG2). Because as compared to ERG2, the expres-
sion ERG1 is 5-fold higher in ECs and accelerates the expression
of mature genes, such as CD31, we focused on ERG1 to drive
ACs into mature rAC-VECs. Whether coexpression of ERG2 in
addition to ERG1 plays a physiological role in enhancing acqui-
sition of mature vascular identity is unknown.
FLI1 and ERG have been implicated in the specification
of hematopoietic cells (De Val and Black, 2009; Lee et al.,
2008). Of note, SCL/TAL1, VAV3, and LMO2 genes that are
coexpressed in both ECs and hematopoietic cells were also
induced in rAC-VECs. However, combinatorial transduction
of ETV2 concomitant with FLI1/ERG1 (along with TGFb inhibi-
tion) did not induce hematopoietic-specific genes (i.e., CD45,
Thrombopoietin receptor) in rAC-VECs. Thus, transient expres-
sion of ETV2 may alter FLI1/ERG1 predilection for hematopoi-
etic specification, directing nascent rAC-VEC transition toward
a vascular fate.
Optimal Ratios of ETS-TFs Augment Production of
Mature rAC-VECs
Transduction of ACs with ETV2 in the absence of ERG1 and FLI1
is sufficient to initiate transcription of EC-specific genes as well
as stimulate the proliferation of ACs, thereby augmenting their
transition into rAC-VECs. However, ETV2 alone fails to turn on
genes that confer rAC-VECs’ vascular maturity. On the other
hand, whereas singular transduction with either FLI1 or ERG1
failed to confer EC identity upon ACs and induce cellular expan-
sion, cotransduction of ERG1/Fli1with transient ETV2was effec-
tive in generating mature and proliferative rAC-VECs. Indeed,
based on the clonal analyses (Figures 3C–3E), we found that
proper stoichiometric ratios of ETV2 relative to FLI1 and ERG1
were key to the generation of proliferative as well as mature
rAC-VECs.
By day 21, a time point in which rAC-VECs have achieved their
maximal maturity, the clonal efficiency of mature rAC-VECs,
such as clone 3, is 20%. Genome-wide 3D-MDS analyses
demonstrated that the transcriptomes of clone 3 and other
similar clones match those of HUVECs and LSECs. Although
the majority of genes expressed in vascular cells were inducedFigure 6. rAC-VECs Establish Functionally Perfused Vessels In Vitro a
(A) In vitro tube formation assay of control ACs, day 21 rAC-VECs, and HUVECs cu
images of different groups are shown. Scale bar, 100 mm.
(B) Control ACs, day 21 rAC-VECs, and HUVECs were treated with labeled Ac-L
(C) In vivo tube formation assay of GFP-labeled control ACs (i, v, and ix), GFP-labe
TGFb inhibition was removed at day 21 (sample A: iii, vii, and xi; sample B: iv,
subcutaneously into NSG mice. Two weeks after implantation, mice were intrave
and sectioned. Immunofluorescence shows control ACs and rAC-VECs in green
counterstain (DAPI) in blue. Scale bar, 50 mm. White arrows indicate the coloca
indicate only isolectin-marked host mouse vessels.
(D and E) In vivo engraftment of day 21 rAC-VECs (GFP labeled) into liver sinusoida
53 105 GFP-labeled day 21 rAC-VECswere transplanted via intrasplenic route, w
minutes later, the spleen was removed to prevent migration back to spleen. Th
Isolectin-B4 and the liver was removed. Immunofluorescence shows control rAC-
human CD31 staining in cyan, and nuclear counterstain (DAPI) in blue. Liver samp
(E) was imaged at low (i–iv: scale bar, 50 mm) and high magnification (v–viii: sca
isolectin-marked (anastomosed) vessels. Orange arrows indicate only isolectin-min these clones, certain genes such as eNOS and GATA3 were
not completely induced. Tissue-specific microenvironmental
cues may be necessary to induce expression of these genes.
Nonetheless, the remarkable proliferative capacity (ETV2 depen-
dent) and vascular maturity (ERG1/FLI1 dependent) of specific
rAC-VEC clones suggest that the optimal combinatorial ratios
of these ETS-TFs within ACs is the major determinant of gener-
ating plentiful stable rAC-VECs.
Expression of FLI1 and ERG1 Is Not Associated with
Malignant Transformation
Aberrant expression of FLI1 can induce leukemia (Cui et al.,
2009) and Ewing Sarcoma (Zhang et al., 1993). ERG overexpres-
sion has also been associated with leukemias (Martens, 2011).
However, in vivo transplantation of rAC-VECs expressing FLI1
and ERG1 in Matrigel plugs for 14 days or in regenerating liver
for 3months did not lead to emergence of angiomas or angiosar-
comas. Long-term expansion of rAC-VECs beyond 80 days
revealed no evidence of malignant transformation. Employing
CGH, we also showed that expansion of rAC-VECs beyond
28 days did not lead to any chromosomal abnormalities. Further-
more, as rAC-VEC phenotype is retained even after removal of
ETV2 expression and TGFb-inhibition, this indicates that rAC-
VECs represent a durable and expandable cell population that
provides for a safe source of vascular cells.
Potential Use of rAC-VECs for Therapeutic
Vascularization and Organ Regeneration
The vascular repertoire of rAC-VECs approximates that of
generic naive ECs. As such, rAC-VECs may have the vascular
plasticity to undergo further tissue-specific specialization once
reintroduced into the microenvironment of a given organ. In
support of this premise, we showed that rAC-VECs acquired
the morphology of sinusoidal ECs upon transplantation into re-
generating liver. Ultimately, identification of the TFs that endow
ECs with a tissue-specific signature will enable generation of
rAC-VECs that will adapt to the physiological and metabolic
needs of a particular organ. In this regard, we have identified
a readily available source of human lineage-committed prolifer-
ative cells with allogeneic compatibility that are amenable to re-
programming into abundant functional rAC-VECs.nd In Vivo
ltured onMatrigel in EM+ TGFb inhibition for 12 hr. Phase-contrast microscopy
DL (DiI label) for 4 hr. Scale bar, 100 mm.
led day 42 rAC-VECs (ii, vi, and x), and GFP-labeled day 42 rAC-VECs in which
viii, and xii). Cells were loaded separately into Matrigel plugs and implanted
nously perfused with Alexa568-Isolectin-B4. After 10 min, plugs were removed
(GFP), intravital labeling of perfused vasculature in red (Isolectin), and nuclear
lization of GFP- and isolectin-marked (anastomosed) vessels. Orange arrows
l vessels of twomice. After performing 70% partial hepatectomy on NSGmice,
hichwill drain into portal circulation and incorporate into liver vasculature. Thirty
ree months following transplantation, the mice were perfused with Alexa568-
VECs in green (GFP), intravital labeling of perfused vasculature in red (Isolectin),
le 1 (D) was imaged at low magnification (i–iv: scale bar, 50 mm). Liver sample 2
le bar, 25 mm). White arrows indicate the colocalization of GFP-, CD31-, and
arked host mouse vessels.
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Figure 7. Transient ETV2 and Constitutive FLI1 and ERG1 Expression, Concomitant with TGFb Inhibition, Generate Long-Lasting rAC-VECs
without Loss of Vascular Identity
(A) FACS reveals expression of VE-cad and CD31 in ACs transduced with iETV2/FLI1/ERG1 for 14 (i), 21 (ii and iii), and 28 (iv and v) days plus TGFb inhibition
(iETV2: inducible ETV2 lentivirus). A subset of these cells (iii and v) was treated with doxycycline (Dox) at day 14 to suppress ETV2 protein.
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The generation of rAC-VECs will not only increase our under-
standing of the hierarchy of transcriptional pathways involved
in the induction and maintenance of organ-specific ECs, but
also open the door for vascularization of ischemic tissues. With
thousands of amniocenteses being performed worldwide each
year, this ensures that sufficient genetically matched ACs will
be available for reprogramming into rAC-VECs that may benefit
a broad cross-section of the ethnically diverse population. Given
that ACs and rAC-VECs could beHLA typed, cryopreserved, and
publicly banked, these cells could establish an inventory for
generating abundant vascular cells for promoting angiocrine-
dependent organ regeneration as well as lay the foundation for





Human embryonic stem cells (hESCs) were maintained on Matrigel using
hESC medium (KOSR) conditioned by mouse embryonic fibroblasts (MEF,
Chemicon) and were grown at 37 at 5% CO2. Amniotic cells (ACs) were
cultured in amniotic media (AM) and grown at 37 at 5% CO2.
In reprogramming assays, ACs were cultured in endothelial growth media
(EM: medium 199, 15% FBS, 20 mg/ml endothelial cell supplement, 13 Pen/
Strep, and 20 units/ml Heparin) and, where indicated, supplemented with
5 mM TGFb inhibitor or 10 mg/ml TGFb ligand-neutralizing mAB (R&D) to inhibit
TGFb signaling. Human liver sinusoidal ECs (LSECs, ScienCell) were cultured
in EM with 20% FBS. Human umbilical vein ECs (HUVECs) were obtained as
previously described (Rafii et al., 1994, 1995) and cultured in EM with 20%
FBS. Culture plates were coated with 1 mg/ml Fibronectin (Sigma), and cells
were grown at 37 and at 5% CO2 and 5% O2. See Extended Experimental
Procedures for details of strains and media.
Cytokine Treatments
For TGFb experiments, 10 ng/ml TGFb ligands b1 and b3 (R&D) were added for
indicated times. For VEGFR2 phosphorylation experiments, 50 ng/ml VEGF-A
was added for 5 min. For acetylated-LDL uptake assays, cells were treated
with 10 mg/ml DiI-labeled Ac-LDL (Biomedical Technical Inc).
Lentiviral Vectors and Transduction Strategy
ETV2, ERG1, and FLI1 cDNAs were cloned into the pCCL-PGK lentivirus
vector. A triple Flag-tag was subcloned into the ETV2 construct at the
amino terminus. For conditional expression/suppression experiments, Flag-
tag ETV2 was resubcloned into an inducible pTA-dependent construct,
in which suppression of Flag-tag ETV2 was achieved via treatment with
2 mg/ml doxycycline (Clonetech). A scrambled shRNA construct was cloned
into the pLKO vector for use as a control. See Extended Experimental Proce-
dures for details of construct strategy and lentiviral production.(B) Percentage of VE-cad+CD31+ cells is shown. White bars: no Dox treatment.
(C) iETV2 suppression by Dox was confirmed by western blot analysis.
(D) In vivo tube formation assay of GFP-labeled day 42 rAC-VECs in which iETV2
plug analysis in NSGmice as previously described in Figure 6C. Immunofluoresce
vasculature in red (Isolectin), human CD31 staining in cyan, and nuclear counters
100 mm). Sample B was imaged at high magnification (v–viii: scale bar, 50 mm). W
(anastomosed) vessels. Orange arrows indicate only isolectin-marked host mou
(E) Modular ETS-TF-mediated reprogramming of ACs into abundant mature rAC-V
ECs, nor do they proliferate (bottom). In the absence of TGFb inhibition, ETS-TF
including functional VEGFR2, resulting in the generation of VEGF-A-unrespons
for3 weeks upregulates and functionalizes VEGFR2, allowing for VEGF-A-depe
along with TGFb inhibition maintains VE-cadherin and VEGFR2 expression; howe
immature EC progenitors (top, low). Upon suppression of ETV2 at day 14, CD31 i
bars represent standard error of triplicate samples.
See also Figures S6 and S7.In Vitro Matrigel Tubulogenesis and In Vivo Angiogenesis Assays
To test the capacity of rAC-VECs to undergo tubulogenesis in vivo, ACs in-
fected with ETS-TFs were transduced with GFP-lentivirus and were mixed
with Matrigel (BD), 100 ng/ml of VEGF-A, and 50 ng/ml of FGF-2 and were
subcutaneously implanted at the flanks of NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
(NOD-SCID/IL2Rg/, NSG) mice (Jackson Laboratories). To test the capacity
of rAC-VECs to functionally incorporate into regenerating liver sinusoidal
vasculature, GFP-labeled rAC-VECs were intrasplenically injected into NSG
mice 2 days after they were subjected to 70% partial hepatectomy, as previ-
ously described (Ding et al., 2010). At 30 min after intrasplenic injection, the
spleenwas removed. Twoweeks (Matrigel plugs) or threemonths (intrasplenic)
after injection of GFP-labeled rAC-VECs, the mice were injected intravenously
with Isolectin-B4 conjugated with Alexa568 (Invitrogen) (2 mg/kg) and were
sacrificed 10 min later. The Matrigel plug or liver was then fixed in 4% parafor-
maldehyde, followed by 48 hr saturation in 30% sucrose. 20 mm cryosections
were made and counterstained with Hoechst 33342. Incorporation of GFP-
labeled rAC-VECs was identified, and functional engraftment into host vascu-
lature was revealed by costaining with Isolectin-B4 fluorescence. Antihuman
CD31 (BD) staining was performed to distinguish rAC-VECs from host mouse
ECs. Fluorescent signal was analyzed by confocal microscopy (710 META
Zeiss). The area of GFP-positive field was quantified by ImageJ, and the
number of isolectin-positive functional vessels was determined by counting
cells present in three fields of view taken at random. For in vitro assays,
200,000 rAC-VECs were seeded on Matrigel-coated plates (200 ml), and tubu-
logenesis was determined as previously described (Kobayashi et al., 2010).
Immunofluorescence/Western Blot Analysis
Samples were stained as previously described (James et al., 2010). In
brief, samples were permeabilized in PBS-Tween and blocked in 5% donkey
serum. Samples were incubated for 1 hr with conjugated antibodies in block-
ing solution, washed, and counterstained for nucleic acids by DAPI or ToPro3
(Invitrogen) for imaging. Western blot analysis was performed as previously
described (Kobayashi et al., 2010). See Extended Experimental Procedures
for details of antibodies used in these assays.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, one table, and one movie and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2012.09.032.
ACKNOWLEDGMENTS
S.R. is supported by Howard Hughes Medical Institute; Ansary StemCell Insti-
tute; Empire State Stem Cell Board and New York State Department of Health
grants (NYSTEM, C024180, C026438, C026878); NHLBI R01s HL097797 and
DK095039; Qatar National Priorities Research Foundation NPRP08-663-
3-140; and Qatar foundation BioMedical Research Program (BMRP). The
authors acknowledge Agnes Stachnik and Pooja Rana for their technical
contribution to this work.Black bars: Dox treatment at day 14.
expression was suppressed at day 14. rAC-VECs were subjected to Matrigel
nce micrographs show rAC-VECs in green (GFP), intravital labeling of perfused
tain (DAPI) in blue. Sample A was imaged at low magnification (i–iv: scale bar,
hite arrows indicate the colocalization of GFP-, CD31- and isolectin-marked
se vessels.
ECs. When cultured in optimal EC conditions, naive ACs do not reprogram into
-transduced ACs are VE-cad+ but fail to express other essential EC-markers,
ive EC-like precursors (shaded panel). Transient inhibition of TGFb signaling
ndent signaling events to proceed (top). Coexpression of FLI1/ERG1with ETV2
ver, constitutive ETV2 inhibits CD31 expression, resulting in the production of
s upregulated, facilitating the generation of mature rAC-VECs (top, high). Error
Cell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc. 573
Received: August 3, 2011
Revised: March 26, 2012
Accepted: September 9, 2012
Published online: October 18, 2012
REFERENCES
Asano, Y., and Trojanowska, M. (2009). Phosphorylation of Fli1 at threonine
312 by protein kinase C delta promotes its interaction with p300/CREB-
binding protein-associated factor and subsequent acetylation in response to
transforming growth factor beta. Mol. Cell. Biol. 29, 1882–1894.
Asano, Y., Stawski, L., Hant, F., Highland, K., Silver, R., Szalai, G., Watson,
D.K., and Trojanowska, M. (2010). Endothelial Fli1 deficiency impairs vascular
homeostasis: a role in scleroderma vasculopathy. Am. J. Pathol. 176, 1983–
1998.
Benavides, O.M., Petsche, J.J., Moise, K.J., Jr., Johnson, A., and Jacot, J.G.
(2012). Evaluation of endothelial cells differentiated from amniotic fluid-derived
stem cells. Tissue Eng. Part A 18, 1123–1131.
Birdsey, G.M., Dryden, N.H., Amsellem, V., Gebhardt, F., Sahnan, K., Haskard,
D.O., Dejana, E., Mason, J.C., and Randi, A.M. (2008). Transcription factor Erg
regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood
111, 3498–3506.
Bossolasco, P., Montemurro, T., Cova, L., Zangrossi, S., Calzarossa, C., Buia-
tiotis, S., Soligo, D., Bosari, S., Silani, V., Deliliers, G.L., et al. (2006). Molecular
and phenotypic characterization of human amniotic fluid cells and their differ-
entiation potential. Cell Res. 16, 329–336.
Butler, J.M., Kobayashi, H., and Rafii, S. (2010a). Instructive role of the
vascular niche in promoting tumour growth and tissue repair by angiocrine
factors. Nat. Rev. Cancer 10, 138–146.
Butler, J.M., Nolan, D.J., Vertes, E.L., Varnum-Finney, B., Kobayashi, H.,
Hooper, A.T., Seandel, M., Shido, K., White, I.A., Kobayashi, M., et al.
(2010b). Endothelial cells are essential for the self-renewal and repopulation
of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6, 251–264.
Cui, J.W., Vecchiarelli-Federico, L.M., Li, Y.J., Wang, G.J., and Ben-David, Y.
(2009). Continuous Fli-1 expression plays an essential role in the proliferation
and survival of F-MuLV-induced erythroleukemia and human erythroleukemia.
Leukemia 23, 1311–1319.
De Coppi, P., Bartsch, G., Jr., Siddiqui, M.M., Xu, T., Santos, C.C., Perin, L.,
Mostoslavsky, G., Serre, A.C., Snyder, E.Y., Yoo, J.J., et al. (2007). Isolation
of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25,
100–106.
De Val, S., and Black, B.L. (2009). Transcriptional control of endothelial cell
development. Dev. Cell 16, 180–195.
De Val, S., Chi, N.C., Meadows, S.M., Minovitsky, S., Anderson, J.P., Harris,
I.S., Ehlers, M.L., Agarwal, P., Visel, A., Xu, S.M., et al. (2008). Combinatorial
regulation of endothelial gene expression by ets and forkhead transcription
factors. Cell 135, 1053–1064.
Ding, B.S., Nolan, D.J., Butler, J.M., James, D., Babazadeh, A.O., Rosenwaks,
Z., Mittal, V., Kobayashi, H., Shido, K., Lyden, D., et al. (2010). Inductive angio-
crine signals from sinusoidal endothelium are required for liver regeneration.
Nature 468, 310–315.
Ding, B.S., Nolan, D.J., Guo, P., Babazadeh, A.O., Cao, Z., Rosenwaks, Z.,
Crystal, R.G., Simons, M., Sato, T.N., Worgall, S., et al. (2011). Endothelial-
derived angiocrine signals induce and sustain regenerative lung alveolariza-
tion. Cell 147, 539–553.
Dryden, N.H., Sperone, A., Martin-Almedina, S., Hannah, R.L., Birdsey, G.M.,
Khan, S.T., Layhadi, J.A., Mason, J.C., Haskard, D.O., Go¨ttgens, B., and
Randi, A.M. (2012). The transcription factor Erg controls endothelial cell quies-
cence by repressing activity of nuclear factor (NF)-kB p65. J. Biol. Chem. 287,
12331–12342.
Hackett, N.R., Butler, M.W., Shaykhiev, R., Salit, J., Omberg, L., Rodriguez-
Flores, J.L., Mezey, J.G., Strulovici-Barel, Y., Wang, G., Didon, L., and Crystal,
R.G. (2012). RNA-Seq quantification of the human small airway epithelium
transcriptome. BMC Genomics 13, 82.574 Cell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc.Hollenhorst, P.C., Shah, A.A., Hopkins, C., and Graves, B.J. (2007). Genome-
wide analyses reveal properties of redundant and specific promoter occu-
pancy within the ETS gene family. Genes Dev. 21, 1882–1894.
James, D., Nam, H.S., Seandel, M., Nolan, D., Janovitz, T., Tomishima, M.,
Studer, L., Lee, G., Lyden, D., Benezra, R., et al. (2010). Expansion and main-
tenance of human embryonic stem cell-derived endothelial cells by TGFbeta
inhibition is Id1 dependent. Nat. Biotechnol. 28, 161–166.
Jezierski, A., Gruslin, A., Tremblay, R., Ly, D., Smith, C., Turksen, K., Sikorska,
M., and Bani-Yaghoub, M. (2010). Probing stemness and neural commitment
in human amniotic fluid cells. Stem Cell Rev. 6, 199–214.
Jin, D.K., Shido, K., Kopp, H.G., Petit, I., Shmelkov, S.V., Young, L.M., Hooper,
A.T., Amano, H., Avecilla, S.T., Heissig, B., et al. (2006). Cytokine-mediated
deployment of SDF-1 induces revascularization through recruitment of
CXCR4+ hemangiocytes. Nat. Med. 12, 557–567.
Kataoka, H., Hayashi, M., Nakagawa, R., Tanaka, Y., Izumi, N., Nishikawa, S.,
Jakt, M.L., Tarui, H., and Nishikawa, S. (2011). Etv2/ER71 induces vascular
mesoderm from Flk1+PDGFRa+ primitive mesoderm. Blood 118, 6975–6986.
Kobayashi, H., Butler, J.M., O’Donnell, R., Kobayashi, M., Ding, B.S., Bonner,
B., Chiu, V.K., Nolan, D.J., Shido, K., Benjamin, L., and Rafii, S. (2010). Angio-
crine factors from Akt-activated endothelial cells balance self-renewal and
differentiation of haematopoietic stem cells. Nat. Cell Biol. 12, 1046–1056.
Ko¨nig, J., Huppertz, B., Desoye, G., Parolini, O., Fro¨hlich, J.D., Weiss, G.,
Dohr, G., Sedlmayr, P., and Lang, I. (2012). Amnion-derived mesenchymal
stromal cells show angiogenic properties but resist differentiation into mature
endothelial cells. Stem Cells Dev. 21, 1309–1320.
Lee, D., Park, C., Lee, H., Lugus, J.J., Kim, S.H., Arentson, E., Chung, Y.S., Go-
mez, G., Kyba, M., Lin, S., et al. (2008). ER71 acts downstream of BMP, Notch,
and Wnt signaling in blood and vessel progenitor specification. Cell Stem Cell
2, 497–507.
Liu, F., and Patient, R. (2008). Genome-wide analysis of the zebrafish ETS
family identifies three genes required for hemangioblast differentiation or
angiogenesis. Circ. Res. 103, 1147–1154.
Liu, F., Walmsley, M., Rodaway, A., and Patient, R. (2008). Fli1 acts at the top
of the transcriptional network driving blood and endothelial development.
Curr. Biol. 18, 1234–1240.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A.,
Heissig, B., Marks, W., Witte, L., et al. (2001). Impaired recruitment of bone-
marrow-derived endothelial and hematopoietic precursor cells blocks tumor
angiogenesis and growth. Nat. Med. 7, 1194–1201.
Margariti, A., Winkler, B., Karamariti, E., Zampetaki, A., Tsai, T.N., Baban, D.,
Ragoussis, J., Huang, Y., Han, J.D., Zeng, L., et al. (2012). Direct reprogram-
ming of fibroblasts into endothelial cells capable of angiogenesis and reendo-
thelialization in tissue-engineered vessels. Proc. Natl. Acad. Sci. USA 109,
13793–13798.
Martens, J.H. (2011). Acute myeloid leukemia: a central role for the ETS factor
ERG. Int. J. Biochem. Cell Biol. 43, 1413–1416.
McLaughlin, F., Ludbrook, V.J., Cox, J., von Carlowitz, I., Brown, S., and
Randi, A.M. (2001). Combined genomic and antisense analysis reveals that
the transcription factor Erg is implicated in endothelial cell differentiation.
Blood 98, 3332–3339.
Pham, V.N., Lawson, N.D., Mugford, J.W., Dye, L., Castranova, D., Lo, B., and
Weinstein, B.M. (2007). Combinatorial function of ETS transcription factors in
the developing vasculature. Dev. Biol. 303, 772–783.
Rafii, S., and Lyden, D. (2003). Therapeutic stem and progenitor cell transplan-
tation for organ vascularization and regeneration. Nat. Med. 9, 702–712.
Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B. (2002). Vascular
and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Nat. Rev. Cancer 2, 826–835.
Rafii, S., Shapiro, F., Rimarachin, J., Nachman, R.L., Ferris, B., Weksler, B.,
Moore, M.A., and Asch, A.S. (1994). Isolation and characterization of human
bone marrow microvascular endothelial cells: hematopoietic progenitor cell
adhesion. Blood 84, 10–19.
Rafii, S., Shapiro, F., Pettengell, R., Ferris, B., Nachman, R.L., Moore, M.A.,
and Asch, A.S. (1995). Human bone marrow microvascular endothelial cells
support long-term proliferation and differentiation of myeloid and megakaryo-
cytic progenitors. Blood 86, 3353–3363.
Reinisch, A., Hofmann, N.A., Obenauf, A.C., Kashofer, K., Rohde, E., Schall-
moser, K., Flicker, K., Lanzer, G., Linkesch, W., Speicher, M.R., and Strunk,
D. (2009). Humanized large-scale expanded endothelial colony-forming cells
function in vitro and in vivo. Blood 113, 6716–6725.
Yoder, M.C., Mead, L.E., Prater, D., Krier, T.R., Mroueh, K.N., Li, F., Krasich,
R., Temm, C.J., Prchal, J.T., and Ingram, D.A. (2007). Redefining endothelial
progenitor cells via clonal analysis and hematopoietic stem/progenitor cell
principals. Blood 109, 1801–1809.
Yuan, L., Nikolova-Krstevski, V., Zhan, Y., Kondo, M., Bhasin, M., Varghese,
L., Yano, K., Carman, C.V., Aird, W.C., and Oettgen, P. (2009). Antiinflamma-
tory effects of the ETS factor ERG in endothelial cells are mediated through
transcriptional repression of the interleukin-8 gene. Circ. Res. 104, 1049–1057.
Yuan, L., Le Bras, A., Sacharidou, A., Itagaki, K., Zhan, Y., Kondo, M., Carman,
C.V., Davis, G.E., Aird, W.C., and Oettgen, P. (2012). ETS-related gene (ERG)
controls endothelial cell permeability via transcriptional regulation of the clau-
din 5 (CLDN5) gene. J. Biol. Chem. 287, 6582–6591.
Zeisberg, E.M., Tarnavski, O., Zeisberg, M., Dorfman, A.L., McMullen, J.R.,
Gustafsson, E., Chandraker, A., Yuan, X., Pu, W.T., Roberts, A.B., et al.(2007). Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.
Nat. Med. 13, 952–961.
Zhang, L., Lemarchandel, V., Romeo, P.H., Ben-David, Y., Greer, P., and Bern-
stein, A. (1993). The Fli-1 proto-oncogene, involved in erythroleukemia and
Ewing’s sarcoma, encodes a transcriptional activator with DNA-binding spec-
ificities distinct from other Ets family members. Oncogene 8, 1621–1630.
Zhang, P., Baxter, J., Vinod, K., Tulenko, T.N., and Di Muzio, P.J. (2009).
Endothelial differentiation of amniotic fluid-derived stem cells: synergism of
biochemical and shear force stimuli. Stem Cells Dev. 18, 1299–1308.Note Added in Proof
Based on recent evidence by Buganim et al. that recently discovered pluripo-
tency factors, including Lin28, Sall4, Dppa2, Utf1, and Esrrb, could potentially
augment reprogramming of somatic cells, we have interrogated our RNA-
sequencing data for the expression of these factors. We observe that amniotic
cells not only lack the expression of Oct4, Sox2, and Nanog, but also fail to
express Lin28, Sall4, Dppa2, Utf1, and Esrrb. These data confirm that our
experimental approach described here enables reprogramming of amniotic
cells into rAC-VECs without transitioning through a pluripotent state. Buganim,
Y., Faddah, D., Cheng, A., Itskovich, E., Markoulaki, S., Ganz, K., Klemm, S.,
Oudenaarden, A., and Jaenisch, R. (2012). Single-cell expression analyses
during cellular reprogramming reveal an early stochastic and a late hierarchic
phase. Cell 150, 1209–1222.Cell 151, 559–575, October 26, 2012 ª2012 Elsevier Inc. 575
